Although CEA and CA-153 were also elevated in the blood of patients with breast cancer, APT had greater accuracy than traditional breast cancer biomarkers (i.e., CEA, CA-125, CA-199, and CA-153) in differentiating patients with breast cancer from those with benign breast nodules and healthy controls. The gene discussed is MUC1; the disease is breast carcinoma.